DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced new pooled efficacy data from the Phase 2 and 3 clinical trials of TEPEZZA™ (teprotumumab-trbw) showing that the ...
Findings showed a statistically significant reduction in proptosis in the linsitinib 150mg twice daily group, with a proptosis responder rate of 52% at week 24. Topline results were announced from a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results